Search research articles
Contact Us
Filters
Showing results (131-140 of 144) with videos related to
Page
of 15
Sort By:
International Journal of Clinical Oncology
|
June 27, 2026
Pretreatment serum vitamin D levels predict the therapeutic efficacy of atezolizumab plus bevacizumab therapy in advanced hepatocellular carcinoma: a multicenter analysis
Takanori Suzuki, Kentaro Matsuura, Satoshi Narahara, et al.
Lung Cancer (Amsterdam, Netherlands)
|
February 2, 2025
First-line nivolumab plus platinum chemotherapy and bevacizumab for advanced nonsquamous non-small cell lung cancer: A 3-year follow-up of the phase 3 randomized TASUKI-52 trial
Ki Hyeong Lee, Jong-Seok Lee, Shunichi Sugawara, et al.
Future Oncology (London, England)
|
February 5, 2026
Plain language summary of TASUKI-52: A study looking at nivolumab plus platinum chemotherapy and bevacizumab as a combined treatment for people with advanced or recurrent nonsquamous non-small cell lung cancer (NSCLC)
Shunichi Sugawara, Jong-Seok Lee, Jin-Hyoung Kang, et al.
Anticancer Research
|
December 8, 2020
Elective Nodal Irradiation for Non-small Cell Lung Cancer Complicated With Chronic Obstructive Pulmonary Disease Affects Immunotherapy Αfter Definitive Chemoradiotherapy
Masahiro Morimoto, Kazumi Nishino, Kentaro Wada, et al.
Cancer Science
|
January 29, 2026
Four-Year Outcomes for Nivolumab With Chemotherapy and Bevacizumab in Patients With Nonsquamous NSCLC in the TASUKI-52
Jong-Seok Lee, Shunichi Sugawara, Jin-Hyoung Kang, et al.
Journal of Clinical Laboratory Analysis
|
June 17, 2026
Improving Linkage to the HCV Care Cascade in Nonspecialist Settings: Evaluation of the Performance and Triage Utility of the Elecsys HCV Duo Assay in Japan
Hiroko Setoyama, Takehisa Watanabe, Shiho Miyase, et al.
Future Oncology (London, England)
|
April 27, 2026
A plain language review of results from the LAURA study: osimertinib after chemoradiotherapy for patients with EGFR-mutated non-small cell lung cancer that cannot be removed by surgery
Shun Lu, Terufumi Kato, Xiaorong Dong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 22, 2024
Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, <i>EGFR</i>-Mutant, Metastatic Nonsquamous Non-Small Cell Lung Cancer
James Chih-Hsin Yang, Dae Ho Lee, Jong-Seok Lee, et al.
The New England Journal of Medicine
|
June 3, 2024
Osimertinib after Chemoradiotherapy in Stage III <i>EGFR</i>-Mutated NSCLC
Shun Lu, Terufumi Kato, Xiaorong Dong, et al.
Ebiomedicine
|
November 2, 2024
Induction of IGHV3-53 public antibodies with broadly neutralising activity against SARS-CoV-2 including Omicron subvariants in a Delta breakthrough infection case
Takeo Kuwata, Yu Kaku, Shashwata Biswas, et al.
Page
of 15
Search research articles
Search
Showing results (131-140 of 144) with videos related to
Sort By:
Page
of 15
International Journal of Clinical Oncology
|
June 27, 2026
Pretreatment serum vitamin D levels predict the therapeutic efficacy of atezolizumab plus bevacizumab therapy in advanced hepatocellular carcinoma: a multicenter analysis
Takanori Suzuki, Kentaro Matsuura, Satoshi Narahara, et al.
Lung Cancer (Amsterdam, Netherlands)
|
February 2, 2025
First-line nivolumab plus platinum chemotherapy and bevacizumab for advanced nonsquamous non-small cell lung cancer: A 3-year follow-up of the phase 3 randomized TASUKI-52 trial
Ki Hyeong Lee, Jong-Seok Lee, Shunichi Sugawara, et al.
Future Oncology (London, England)
|
February 5, 2026
Plain language summary of TASUKI-52: A study looking at nivolumab plus platinum chemotherapy and bevacizumab as a combined treatment for people with advanced or recurrent nonsquamous non-small cell lung cancer (NSCLC)
Shunichi Sugawara, Jong-Seok Lee, Jin-Hyoung Kang, et al.
Anticancer Research
|
December 8, 2020
Elective Nodal Irradiation for Non-small Cell Lung Cancer Complicated With Chronic Obstructive Pulmonary Disease Affects Immunotherapy Αfter Definitive Chemoradiotherapy
Masahiro Morimoto, Kazumi Nishino, Kentaro Wada, et al.
Cancer Science
|
January 29, 2026
Four-Year Outcomes for Nivolumab With Chemotherapy and Bevacizumab in Patients With Nonsquamous NSCLC in the TASUKI-52
Jong-Seok Lee, Shunichi Sugawara, Jin-Hyoung Kang, et al.
Journal of Clinical Laboratory Analysis
|
June 17, 2026
Improving Linkage to the HCV Care Cascade in Nonspecialist Settings: Evaluation of the Performance and Triage Utility of the Elecsys HCV Duo Assay in Japan
Hiroko Setoyama, Takehisa Watanabe, Shiho Miyase, et al.
Future Oncology (London, England)
|
April 27, 2026
A plain language review of results from the LAURA study: osimertinib after chemoradiotherapy for patients with EGFR-mutated non-small cell lung cancer that cannot be removed by surgery
Shun Lu, Terufumi Kato, Xiaorong Dong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 22, 2024
Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, <i>EGFR</i>-Mutant, Metastatic Nonsquamous Non-Small Cell Lung Cancer
James Chih-Hsin Yang, Dae Ho Lee, Jong-Seok Lee, et al.
The New England Journal of Medicine
|
June 3, 2024
Osimertinib after Chemoradiotherapy in Stage III <i>EGFR</i>-Mutated NSCLC
Shun Lu, Terufumi Kato, Xiaorong Dong, et al.
Ebiomedicine
|
November 2, 2024
Induction of IGHV3-53 public antibodies with broadly neutralising activity against SARS-CoV-2 including Omicron subvariants in a Delta breakthrough infection case
Takeo Kuwata, Yu Kaku, Shashwata Biswas, et al.
Page
of 15